These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27259210)

  • 21. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?
    Alexopoulos D; Moulias A; Kanakakis I; Xanthopoulou I
    Int J Cardiol; 2015 Sep; 194():41-3. PubMed ID: 26011263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
    Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
    Floyd CN; Passacquale G; Ferro A
    Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
    Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
    Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.